Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton's Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström Macroglobulinemia

Wataru Munakata, Naohiro Sekiguchi, MD PhD, Rai Shinya, MD,PhD, Kenshi Suzuki, MD PhD, Hiroshi Handa, MD PhD, Hirohiko Shibayama, MD PhD, Tomoyuki Endo, MD PhD, Yasuhito Terui, MD PhD, Noriko Iwaki, MD PhD, Noriko Fukuhara, MD PhD, Hiro Tatetsu, MD PhD, Shinsuke Iida, MD PhD, Takayuki Ishikawa, MD PhD, Ryota Shiibashi, Koji Izutsu, MD PhD

Blood (2019) 134 (Supplement_1): 345.

https://doi.org/10.1182/blood-2019-124614

Published: 2019

Journal Articles

PU.1-Induced IRF4 Down-Regulation and Subsequent IRF7 up-Regulation in Myeloma Cells

Niina Ueno, MD, Shikiko Ueno, MD PhD, Shinya Endo, MD, Nao Nishimura, MD, Hiro Tatetsu, MD PhD, Shinya Hirata, MD PhD, Hiroaki Mitsuya, MD PhD, Yutaka Okuno, MD PhD

Blood (2015) 126 (23): 2957.

https://doi.org/10.1182/blood.V126.23.2957.2957

Published: 2015

Journal Articles

Conditional Knockout of Sfpi1 in Post GC B and Plasma Cells Induces B Cell Lymphoma and Plasma Cell Neoplasm

Shinya Endo, MD, Hiromichi Yuki, MD PhD, Yoshihiro Komohara, MD PhD, Shikiko Ueno, MD PhD, Nao Nishimura, MD, Niina Ueno, MD, Hiro Tatetsu, MD PhD, Motohiro Takeya, MD PhD, Hiroyuki Hata, MD PhD, Seiji Okada, MD PhD, Daniel G. Tenen, MD, Hiroaki Mitsuya, MD PhD, Yutaka Okuno, MD PhD

Blood (2014) 124 (21): 29.

https://doi.org/10.1182/blood.V124.21.29.29

Published: 2014

Journal Articles

SALL4 Is a Key Factor in HDAC Inhibitor Mediated Ex Vivo Expansion of Human Peripheral Blood Mobilized Stem/Progenitor CD34+CD90+ Cells

Hiro Tatetsu, MD PhD, Fei Wang, Chong Gao, MD PhD, Shikiko Ueno, MD PhD, Xi Tian, BS, Myriam Armant, PhD, Alex Federation, Jun Qi, PhD, James E. Bradner, Daniel G. Tenen, MD, Li Chai, MD

Blood (2014) 124 (21): 1566.

https://doi.org/10.1182/blood.V124.21.1566.1566

Published: 2014

Journal Articles

A Novel Approach in Expanding CD34+CD90+ and CD34+CD38-CD90+ Cells Associated with Enhanced in Vivo Repopulating potential.

Hiro Tatetsu, MD, PhD, Chong Gao, MD, PhD, Shikiko Ueno, MD, PhD, Daniel G Tenen, MD, Li Chai, MD

Blood (2012) 120 (21): 2337.

https://doi.org/10.1182/blood.V120.21.2337.2337

Published: 2012

Journal Articles

PU.1-Induced Growth Arrest and Apoptosis in Classical Hodgkin Lymphoma Cells

Hiromichi Yuki, MD, Shikiko Ueno, MD, PhD, Hiroaki Niiro, MD, PhD, Hiro Tatetsu, MD, PhD, Hiroyuki Hata, MD, PhD, Toshiki Watanabe, MD, PhD, Seiji Okada, MD, Ph.D, Koichi Akashi, MD, PhD., Hiroaki Mitsuya, Professor, Yutaka Okuno, MD, PhD

Blood (2011) 118 (21): 2628.

https://doi.org/10.1182/blood.V118.21.2628.2628

Published: 2011

Journal Articles

Decreased CD138 Expression in Myeloma Cells: A Potential Indicator of Poor Prognosis and Aberrant Differentiation,

Yawara Kawano, MD, Shiho Fujiwara, MD, Hiromichi Yuki, MD, Hiro Tatetsu, MD, PhD, Hiroshi Yamasaki, MD, PhD, Akira Sakai, MD, PhD, Yutaka Okuno, MD, PhD, Hiroaki Mitsuya, MD, PhD, Hiroyuki Hata, MD, PhD

Blood (2011) 118 (21): 3939.

https://doi.org/10.1182/blood.V118.21.3939.3939

Published: 2011

NARROW

Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton's Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström Macroglobulinemia

PU.1-Induced IRF4 Down-Regulation and Subsequent IRF7 up-Regulation in Myeloma Cells

Conditional Knockout of Sfpi1 in Post GC B and Plasma Cells Induces B Cell Lymphoma and Plasma Cell Neoplasm

SALL4 Is a Key Factor in HDAC Inhibitor Mediated Ex Vivo Expansion of Human Peripheral Blood Mobilized Stem/Progenitor CD34+CD90+ Cells

A Novel Approach in Expanding CD34+CD90+ and CD34+CD38-CD90+ Cells Associated with Enhanced in Vivo Repopulating potential.

PU.1-Induced Growth Arrest and Apoptosis in Classical Hodgkin Lymphoma Cells

Decreased CD138 Expression in Myeloma Cells: A Potential Indicator of Poor Prognosis and Aberrant Differentiation,

Email alerts

ASH Publications

American Society of Hematology

Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton's Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström Macroglobulinemia

PU.1-Induced IRF4 Down-Regulation and Subsequent IRF7 up-Regulation in Myeloma Cells

Conditional Knockout of Sfpi1 in Post GC B and Plasma Cells Induces B Cell Lymphoma and Plasma Cell Neoplasm

SALL4 Is a Key Factor in HDAC Inhibitor Mediated Ex Vivo Expansion of Human Peripheral Blood Mobilized Stem/Progenitor CD34+CD90+ Cells

A Novel Approach in Expanding CD34+CD90+ and CD34+CD38-CD90+ Cells Associated with Enhanced in Vivo Repopulating potential.

PU.1-Induced Growth Arrest and Apoptosis in Classical Hodgkin Lymphoma Cells

Decreased CD138 Expression in Myeloma Cells: A Potential Indicator of Poor Prognosis and Aberrant Differentiation,

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only